Department of Obstetrics and Gynecology, Ohio State University, Columbus, Ohio.
The George Washington University Biostatistics Center, Washington, District of Columbia.
Am J Perinatol. 2024 May;41(S 01):e594-e600. doi: 10.1055/a-1925-1435. Epub 2022 Aug 16.
Administration of antenatal corticosteroids (ANCS) is recommended for individuals expected to deliver between 24 and 34 weeks of gestation. Properly timed administration of ANCS achieves maximal benefit. However, more than 50% of individuals receive ANCS outside the recommended window. This study aimed to examine maternal and hospital factors associated with suboptimal receipt of ANCS among individuals who deliver between 24 and 34 weeks of gestation.
Secondary analysis of the Assessment of Perinatal Excellence (APEX), an observational study of births to 115,502 individuals at 25 hospitals in the United States from March 2008 to February 2011, was conducted. Data from 3,123 individuals who gave birth to a nonanomalous live-born infant between 24 to 34 weeks of gestation, had prenatal records available at delivery, and data available on the timing of ANCS use were included in this analysis. Eligible individuals' ANCS status was categorized as optimal (full course completed >24 hours after ANCS but not >7 days before birth) or suboptimal (none, too late, or too early). Maternal and hospital-level variables were compared using optimal as the referent group. Hierarchical multinomial logistic regression models, with site as a random effect, were used to identify maternal and hospital-level characteristics associated with optimal ANCS use.
Overall, 83.6% (2,612/3,123) of eligible individuals received any treatment: 1,216 (38.9%) optimal and 1,907 (61.1%) suboptimal. Within suboptimal group, 495 (15.9%) received ANCS too late, 901 (28.9%) too early, and 511 (16.4%) did not receive any ANCS. Optimal ANCS varied depending on indication for hospital admission ( < 0.001). Individuals who were admitted with intent to deliver were less likely to receive optimal ANCS while individuals admitted for hypertensive diseases of pregnancy were most likely to receive optimal ANCS (10 vs. 35%). The median gestational age of individuals who received optimal ANCS was 31.0 weeks. Adjusting for hospital factors, hospitals with electronic medical records and who receive transfers have fewer eligible individuals who did not receive ANCS. ANCS administration and timing varied substantially by hospital, optimal frequencies ranged from 9.1 to 51.3%, and none frequencies from 6.1 to 61.8%. When evaluating variation by hospital site, models with maternal and hospital factors did not explain any of the variation in ANCS use.
Optimal ANCS use varied by maternal and hospital factors and by hospital site, indicating opportunities for improvement.
· Majority of individuals who deliver between 24 and 34 weeks of gestation do not receive properly timed antenatal corticosteroids.. · Optimal use of antenatal corticosteroids varies by maternal and hospital factors and hospital site.. · Significant variation in hospital sites regarding optimally timed administration of antenatal corticosteroids indicates opportunities for improvement..
建议对预计在 24 至 34 周之间分娩的个体给予产前皮质激素(ANCS)。ANCS 的适当时间给药可达到最大的益处。但是,超过 50%的人在推荐的时间窗之外接受 ANCS。本研究旨在研究与 24 至 34 周之间分娩的个体接受 ANCS 不理想相关的产妇和医院因素。
对来自美国 25 家医院的 115,502 名个体的围产期卓越评估(APEX)的二次分析,该研究于 2008 年 3 月至 2011 年 2 月进行。对 3,123 名在 24 至 34 周之间分娩非畸形活产儿的个体进行了数据分析,这些个体在分娩时具有产前记录,并且可以获得 ANCS 使用时间的数据。将个体的 ANCS 状态分为最佳(完全完成> 24 小时,但距出生前不超过 7 天)或不理想(无,过晚或过早)。使用最佳作为参考组,比较产妇和医院水平的变量。使用分层多项逻辑回归模型,以站点为随机效应,确定与最佳 ANCS 使用相关的产妇和医院水平特征。
总体而言,83.6%(2,612/3,123)的合格个体接受了任何治疗:1,216(38.9%)最佳,1,907(61.1%)不理想。在不理想的群体中,有 495(15.9%)接受了过晚的 ANCS,901(28.9%)过早,511(16.4%)未接受任何 ANCS。最佳 ANCS 的使用取决于入院的原因(<0.001)。打算分娩的人接受最佳 ANCS 的可能性较小,而因妊娠高血压疾病入院的人接受最佳 ANCS 的可能性最大(10 比 35%)。接受最佳 ANCS 的个体的中位孕龄为 31.0 周。在调整医院因素后,具有电子病历和接受转院的医院中,没有接受 ANCS 的合格个体更少。ANCS 的给药和时间安排在医院之间有很大差异,最佳频率范围为 9.1%至 51.3%,无频率范围为 6.1%至 61.8%。在评估医院站点的差异时,带有产妇和医院因素的模型无法解释 ANCS 使用的任何差异。
最佳的 ANCS 使用因产妇和医院因素以及医院地点而异,表明有改进的机会。
·大多数在 24 至 34 周之间分娩的个体未接受适当时间的产前皮质激素治疗。·产前皮质激素的最佳使用因产妇和医院因素以及医院地点而异。·在优化产前皮质激素给药方面,医院之间存在显著差异,表明有改进的机会。